Table 3.

Summary of final neurologic examinations and neurologic consultations. Neurological examinations were performed per protocol by study investigators. Data are n (%).

	Placebo, n = 208	Tanezumab 5 mg^†, n = 206	Study 1015 Tanezumab 10 mg^†, 500 n = 208	Naproxen mg BID, n = 206	Placebo, n = 209	Tanezumab 5 mg^†, n = 211	Study 1018 Tanezumab 10 mg^†, n = 209	Naproxen 500 mg BID, n = 211
Final neurological examination assessments
New or worsened abnormality
Clinically significant	0	1 (0.5)	1 (0.5)	1 (0.5)	0	1 (0.5)	1 (0.5)	1 (0.5)
Not clinically significant	27 (13.0)	24 (11.8)	23 (11.2)	14 (6.8)	14 (6.9)	17 (8.2)	19 (9.3)	20 (9.9)
No new or worsened abnormality	180 (87.0)	179 (87.7)	181 (88.3)	191 (92.7)	189 (93.1)	190 (91.3)	184 (90.2)	181 (89.6)
Final neurological consultation categorization ^‡
Subjects referred for consultation	10 (4.8)	20 (9.7)	38 (18.3)	10 (4.9)	3 (1.4)	20 (9.5)	25 (12.0)	9 (4. 3)
Symptoms, clinically significant signs, or diagnostic tests suggestive of new or worsened peripheral neuropathy	1 (0.5)	6 (2.9)	19 (9.1)	2 (1.0)	2 (1.0)	4 (1.9)	7 (3.3)	3 (1.4)
Other neurological symptoms or signs	3 (1.4)	4 (1.9)	8 (3.8)	3 (1.5)	1 (0.4)	11 (5.2)	9 (4.3)	2 (0.9)
No neurological symptoms or signs	6 (2.9)	10 (4.9)	11 (5.3)	5 (2.4)	0	5 (2.4)	9 (4.3)	4 (1.9)

↵† Administered intravenously on Day 1 and Day 57 (Week 8).
↵‡ Neurological consultations were performed by neurologists following a neurological adverse event report or after significant neurological examination abnormalities were detected by investigators.